Evidence map›Paper›PMID 37391590›Full record

ReviewNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2024

Ethical considerations in rapid and novel treatments in psychiatry.

Tobias Haeusermann, Winston Chiong

Erratum issuedOpen access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Tobias HaeusermannUCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA.
Winston ChiongUCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA. winston.chiong@ucsf.edu.ORCID 0000-0001-9188-1920
University of California, San Francisco · US

Funding

Anticipating ethical challenges and disparities in the dissemination of novel neurotechnologiesR01MH126997 · NIMH · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI CHIONG, WINSTON, DOHAN, DANIEL P. · 2021 to 2024
$1.7M
NIMH NIH HHS R01 MH126997
6 · The paper itself

Abstract

New treatment modalities for mental illness are deeply needed, and emerging therapeutic agents such as psychedelics, ketamine, and neuromodulatory technologies have been welcomed by many researchers and patients. These treatment approaches have also been observed to raise novel ethical questions, and to pose new and different versions of familiar ethical questions in clinical treatment and research. We present an overview and introduction to these issues organized around three specific domains of ethical concern: informed consent, the role of expectancy in clinical response, and distributive justice.

Indexed as

Mental DisordersPsychiatryHumansInformed Consent

Identifiers

PMID37391590
PMCPMC10700644
OpenAlexW4382680834

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.